Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2026-03-04 00:00:00 ET · period of report 2026-03-02 · accession 0001193125-26-091440 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | 2026-03-02 | AMLX | Bedrosian Camille L | Chief Medical Off | S - Sale | $14.58 | -6,461 | 169.3K | -4% | -$94.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-02 | S | D | 6,461 | $14.58 | 169,295 | D | — | — | (F1) Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.440 to $14.945. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |